U.S. markets closed

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
22.75-1.01 (-4.25%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close23.76
Open24.50
Bid22.99 x 1000
Ask26.50 x 800
Day's Range21.51 - 24.73
52 Week Range21.51 - 56.59
Volume414,537
Avg. Volume242,065
Market Cap1.745B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season
    Zacks

    Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season

    ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
    Business Wire

    ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference

    ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m. ET.

  • LTRN: $69 Million Raise & New Programs Spark Price Target Increase
    Zacks Small Cap Research

    LTRN: $69 Million Raise & New Programs Spark Price Target Increase

    By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT On January 20th, 2021, Lantern Pharma Inc. (NASDAQ:LTRN) announced that it had closed a public offering with gross proceeds of $69 million, giving the firm ample resources to achieve important clinical milestones. In addition, Lantern has also added an indication in atypical teratoid rhabdoid tumors (ATRT), details for which